{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T08:31:02Z","timestamp":1782203462739,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.atherosclerosis.2022.08.017","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T21:35:32Z","timestamp":1662759332000},"page":"13-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Efficacy and safety of lomitapide in familial chylomicronaemia syndrome"],"prefix":"10.1016","volume":"359","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1259-8284","authenticated-orcid":false,"given":"Angelo B.","family":"Cefal\u00f9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"D'Erasmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-5544","authenticated-orcid":false,"given":"Gabriella","family":"Iannuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-2829","authenticated-orcid":false,"given":"Davide","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-3049","authenticated-orcid":false,"given":"Antonina","family":"Giammanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Montali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7096-5201","authenticated-orcid":false,"given":"Alberto","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3146-9173","authenticated-orcid":false,"given":"Patrizia","family":"Suppressa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo M.","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"Ganci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Vernuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Caldarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Ciaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-0883","authenticated-orcid":false,"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.017_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.017_bib2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia--current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2022.08.017_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2018.12.019","article-title":"Chylomicronemia: differences between familial chylomicronemia syndrome and multifactorial chylomicronemia","volume":"283","author":"Paquette","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.017_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12944-020-01302-x","article-title":"The burden of familial chylomicronemia syndrome in Canadian patients","volume":"19","author":"Gaudet","year":"2020","journal-title":"Lipids Health Dis."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.017_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","article-title":"Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia","volume":"287","author":"Baass","year":"2020","journal-title":"J. Intern. Med."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2022.08.017_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11883-021-00967-8","article-title":"Rare treatments for rare dyslipidemias: new perspectives in the treatment of homozygous familial hypercholesterolemia (HoFH) and familial chylomicronemia syndrome (FCS)","volume":"23","author":"D'Erasmo","year":"2021","journal-title":"Curr. Atherosclerosis Rep."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.017_bib7","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"Journal of clinical lipidology"},{"key":"10.1016\/j.atherosclerosis.2022.08.017_bib8","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/DDDT.S224771","article-title":"Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design, development and place in therapy","volume":"14","author":"Esan","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.017_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/14779072.2020.1768848","article-title":"Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia","volume":"18","author":"Nurmohamed","year":"2020","journal-title":"Expet Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.atherosclerosis.2022.08.017_bib10","doi-asserted-by":"crossref","first-page":"E299","DOI":"10.1016\/j.atherosclerosis.2021.06.901","article-title":"A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia","volume":"331","author":"Rosenson","year":"2021","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.017_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1194\/jlr.R200014-JLR200","article-title":"Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly","volume":"44","author":"Hussain","year":"2003","journal-title":"J. Lipid Res."},{"issue":"6441","key":"10.1016\/j.atherosclerosis.2022.08.017_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/365065a0","article-title":"Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia","volume":"365","author":"Sharp","year":"1993","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.017_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9860","key":"10.1016\/j.atherosclerosis.2022.08.017_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.017_bib15","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","article-title":"Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients","volume":"97","author":"Carpentier","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2022.08.017_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosis.2015.12.036","article-title":"Myristic acid is associated to low plasma HDL cholesterol levels in a Mediterranean population and increases HDL catabolism by enhancing HDL particles trapping to cell surface proteoglycans in a liver hepatoma cell model","volume":"246","author":"Noto","year":"2016","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.017_bib17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1148\/027153330290051277","article-title":"Invited commentary","volume":"29","author":"Sirlin","year":"2009","journal-title":"Radiographics"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.017_bib18","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1007\/s00261-015-0385-0","article-title":"Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease","volume":"40","author":"Idilman","year":"2015","journal-title":"Abdom. Imag."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.017_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2022.08.017_bib20","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.017_bib21","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12325-017-0531-x","article-title":"Efficacy of lomitapide in the treatment of familial homozygous hypercholesterolemia: results of a real-world clinical Experience in Italy","volume":"34","author":"D'Erasmo","year":"2017","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2022.08.017_bib22","doi-asserted-by":"crossref","first-page":"878","DOI":"10.5551\/jat.34777","article-title":"MTP gene variants and response to lomitapide in patients with homozygous familial hypercholesterolemia","volume":"23","author":"Kolovou","year":"2016","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2022.08.017_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2016.05.005","article-title":"Lomitapide affects HDL composition and function","volume":"251","author":"Yahya","year":"2016","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.017_bib24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/dmr.5610070303","article-title":"The role of the cholesteryl ester transfer protein in lipoprotein metabolism","volume":"7","author":"Swenson","year":"1991","journal-title":"Diabetes Metab. Rev."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.017_bib25","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/0016-5085(91)90535-S","article-title":"Apolipoprotein synthesis in normal and abetalipoproteinemic intestinal mucosa","volume":"101","author":"Glickman","year":"1991","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2022.08.017_bib26","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-2275(20)39776-5","article-title":"In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism","volume":"35","author":"Ikewaki","year":"1994","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.017_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/CIRCULATIONAHA.117.028208","article-title":"Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia","volume":"136","author":"Blom","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2022.08.017_bib28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","article-title":"Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide","volume":"174","author":"Sacks","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2022.08.017_bib29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12020-020-02506-y","article-title":"Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome","volume":"71","author":"Cefalu","year":"2021","journal-title":"Endocrine"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2022.08.017_bib30","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1080\/14656566.2020.1787380","article-title":"Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia","volume":"21","author":"D'Erasmo","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2022.08.017_bib31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2022.08.017_bib32","series-title":"Akcea Therapeutics","year":"2021"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2022.08.017_bib33","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2022.08.017_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022014125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915022014125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:50:04Z","timestamp":1758156604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915022014125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"alternative-id":["S0021915022014125"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.08.017","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of lomitapide in familial chylomicronaemia syndrome","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}